$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000147929019000109 Filed on November 04, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q3
Revenue	$89.00K	$46.00K	$2.362M
YoY Change	-81.72%	-98.05%	3049.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$18.77M	$16.74M	$14.16M
YoY Change	40.49%	18.26%	54.73%
% of Gross Profit
Research & Development	$27.49M	$25.85M	$21.85M
YoY Change	7.68%	18.3%	0.95%
% of Gross Profit
Depreciation & Amortization	$760.0K	$730.0K	$440.0K
YoY Change	58.33%	65.91%	15.79%
% of Gross Profit
Operating Expenses	$46.26M	$42.59M	$36.00M
YoY Change	18.95%	18.28%	16.93%
Operating Profit	-$46.17M	-$42.54M	-$33.64M
YoY Change	20.2%	26.45%	9.52%
Interest Expense	$980.0K	$0.00	$0.00
YoY Change	5.38%		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$130.0K	-$130.0K	-$144.0K
YoY Change	-13.33%	-9.72%	12.5%
Pretax Income	-$45.33M	-$41.41M	-$32.83M
YoY Change	20.49%	26.13%	7.11%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$45.33M	-$41.41M	-$32.83M
YoY Change	11.6%	26.12%	7.12%
Net Earnings / Revenue	-50928.09%	-90019.57%	-1390.09%
Basic Earnings Per Share
Diluted Earnings Per Share	-$993.0K	-$956.1K	-$905.2K
COMMON SHARES
Basic Shares Outstanding	45.11M shares	44.10M shares	36.94M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$290.1M	$209.0M	$208.4M
YoY Change	65.02%	0.29%	35.85%
Cash & Equivalents	$171.2M	$58.92M	$45.13M
Short-Term Investments	$119.0M	$150.1M	$163.3M
Other Short-Term Assets	$6.500M	$6.500M	$7.500M
YoY Change	27.45%	-13.33%	167.86%
Inventory	$0.00
Prepaid Expenses
Receivables	$0.00	$5.000M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$296.6M	$220.6M	$215.9M
YoY Change	42.65%	2.17%	38.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.76M	$14.92M	$13.49M
YoY Change	2.12%	10.55%	17.33%
Goodwill	$0.00
YoY Change
Intangibles	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.669M	$2.519M	$2.944M
YoY Change	-48.6%	-14.44%	252.15%
Total Long-Term Assets	$43.69M	$45.24M	$17.17M
YoY Change	137.08%	163.55%	32.91%
TOTAL ASSETS
Total Short-Term Assets	$296.6M	$220.6M	$215.9M
Total Long-Term Assets	$43.69M	$45.24M	$17.17M
Total Assets	$340.3M	$265.8M	$233.1M
YoY Change	50.34%	14.06%	37.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.010M	$6.902M	$7.341M
YoY Change	-5.03%	-5.98%	9.9%
Accrued Expenses	$18.64M	$18.69M	$15.72M
YoY Change	24.67%	18.93%	30.23%
Deferred Revenue	$7.911M	$5.241M	$8.749M
YoY Change	-7.88%	-40.1%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$40.98M	$34.15M	$31.81M
YoY Change	28.18%	7.38%	48.11%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$73.80M	$80.40M	$19.10M
YoY Change	51.23%	320.94%
Total Long-Term Liabilities	$73.80M	$80.40M	$19.10M
YoY Change	51.23%	320.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.98M	$34.15M	$31.81M
Total Long-Term Liabilities	$73.80M	$80.40M	$19.10M
Total Liabilities	$114.8M	$114.5M	$50.95M
YoY Change	42.21%	124.78%	87.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$844.2M	-$798.9M	-$644.2M
YoY Change	23.28%	24.02%	27.24%
Common Stock	$1.070B	$950.1M	$826.4M
YoY Change	28.82%	14.97%	27.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$225.5M	$151.3M	$182.1M
YoY Change
Total Liabilities & Shareholders Equity	$340.3M	$265.8M	$233.1M
YoY Change	50.34%	14.06%	37.75%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q3
OPERATING ACTIVITIES
Net Income	-$45.33M	-$41.41M	-$32.83M
YoY Change	11.6%	26.12%	7.12%
Depreciation, Depletion And Amortization	$760.0K	$730.0K	$440.0K
YoY Change	58.33%	65.91%	15.79%
Cash From Operating Activities	-$33.51M	-$31.95M	-$25.41M
YoY Change	7.61%	25.74%	18.35%
INVESTING ACTIVITIES
Capital Expenditures	-$290.0K	-$1.480M	-$3.030M
YoY Change	-82.1%	-51.16%	471.7%
Acquisitions
YoY Change
Other Investing Activities	$31.21M	$2.400M	$33.39M
YoY Change	-48.6%	-92.81%	122.6%
Cash From Investing Activities	$30.92M	$920.0K	$30.36M
YoY Change	-47.68%	-96.97%	109.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	114.8M	-80.00K	900.0K
YoY Change	71668.75%	-108.89%	-90.13%
NET CHANGE
Cash From Operating Activities	-33.51M	-31.95M	-25.41M
Cash From Investing Activities	30.92M	920.0K	30.36M
Cash From Financing Activities	114.8M	-80.00K	900.0K
Net Change In Cash	112.2M	-31.11M	5.850M
YoY Change	299.15%	-631.79%	175.94%
FREE CASH FLOW
Cash From Operating Activities	-$33.51M	-$31.95M	-$25.41M
Capital Expenditures	-$290.0K	-$1.480M	-$3.030M
Free Cash Flow	-$33.22M	-$30.47M	-$22.38M
YoY Change	12.53%	36.15%	6.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36975203	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44108407	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Transition Report DocumentTransitionReport	false
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36975203	shares
CY2018	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	dei	Entity File Number EntityFileNumber	001-36297
	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0551645
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7555 Gateway Boulevard
	dei	Entity Address City Or Town EntityAddressCityOrTown	Newark
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94560
	dei	City Area Code CityAreaCode	510
	dei	Local Phone Number LocalPhoneNumber	742-3400
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	RVNC
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Shell Company EntityShellCompany	false
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45108360	shares
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58922000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73256000	USD
CY2019Q3	us-gaap	Short Term Investments ShortTermInvestments	150110000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	102556000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5000000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27000000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6536000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8434000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6902000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5110000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	220568000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	207922000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14917000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14449000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27078000	USD
CY2019Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	730000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	730000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2519000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3247000	USD
CY2019Q3	us-gaap	Assets Assets	265812000	USD
CY2018Q4	us-gaap	Assets Assets	226348000	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18694000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14948000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5241000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8588000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3317000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	34154000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31970000	USD
CY2019Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2892000	USD
CY2018Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2753000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	50707000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	42684000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26778000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3319000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	114531000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	80726000	USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	44000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	37000	USD
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	950073000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	830368000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	42000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-798878000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-684775000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	66968000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	151281000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	145622000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	265812000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226348000	USD
CY2019Q3	us-gaap	Revenues Revenues	46000	USD
CY2018Q3	us-gaap	Revenues Revenues	2362000	USD
	us-gaap	Revenues Revenues	324000	USD
	us-gaap	Revenues Revenues	3242000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25847000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21848000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	75368000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16739000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14155000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	43245000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40505000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	42586000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	36003000	USD
	us-gaap	Operating Expenses OperatingExpenses	118613000	USD
	us-gaap	Operating Expenses OperatingExpenses	107473000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-42540000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-33641000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-118289000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-104231000	USD
CY2019Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1329000	USD
CY2018Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	996000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	4495000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	3099000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	0	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	44000	USD
CY2019Q3	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-68000	USD
CY2018Q3	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-45000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-139000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-150000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-130000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-144000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-170000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-626000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-41409000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-32834000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-114103000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-101952000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-74000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	90000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	50000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-133000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41483000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32744000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-114053000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102085000	USD
CY2019Q3	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-41409000	USD
CY2018Q3	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-32834000	USD
	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-114103000	USD
	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-101952000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.96
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.91
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.67
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.82
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43314831	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36272445	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42730983	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36116745	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44108407	shares
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	151281000	USD
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36992122	shares
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	182098000	USD
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44108407	shares
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	151281000	USD
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36992122	shares
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	182098000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-114103000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-101952000	USD
	us-gaap	Depreciation Depreciation	2152000	USD
	us-gaap	Depreciation Depreciation	1251000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2215000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	904000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12882000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12422000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	7000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1480000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1889000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4676000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	21758000	USD
	rvnc	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	1903000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-72653000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73105000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2950000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5367000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	228568000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	212197000	USD
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	418000	USD
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	178000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-22000000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1426000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5141000	USD
	rvnc	Increase Decreasein Operating Lease Rightof Use Assets IncreaseDecreaseinOperatingLeaseRightofUseAssets	2414000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-999000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1919000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1050000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	793000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3532000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	183000000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	50000000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1537000	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	100000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-48511000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-166127000	USD
	rvnc	Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount	108100000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	480000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4822000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1229000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1906000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	521000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	366000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	932000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	106830000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1618000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-14334000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-237614000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73986000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	283476000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59652000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45862000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	313000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	3000000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	920000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-41400000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-114100000	USD
CY2019Q3	rvnc	Working Capital Surplus WorkingCapitalSurplus	186400000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-798900000	USD
CY2019Q3	rvnc	Contractwith Customer Liability Net ContractwithCustomerLiabilityNet	209000000.0	USD
	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include revenue recognition, deferred revenue, accruals including clinical trial accruals, stock-based compensation, fair value of derivative liability, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.</span></div>
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24700000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	28200000	USD
CY2019Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	3500000	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	Medicis Settlement<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2009, the Company and Medicis Pharmaceutical Corporation (“Medicis”) entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational botulinum toxin type A product candidate. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of DAXI and DaxibotulinumtoxinA Topical from Medicis and for consideration payable by the Company to Medicis of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0</span></span><span style="font-family:inherit;font-size:10pt;"> million, comprised of (i) an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0</span></span><span style="font-family:inherit;font-size:10pt;"> million, which was paid in 2012, (ii) a proceeds sharing arrangement payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.0</span></span><span style="font-family:inherit;font-size:10pt;"> million due upon specified capital raising achievements by the Company, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$6.9</span></span><span style="font-family:inherit;font-size:10pt;"> million was paid in 2013 and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1</span></span><span style="font-family:inherit;font-size:10pt;"> million in 2014, and (iii) a product approval payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0</span></span><span style="font-family:inherit;font-size:10pt;"> million to be paid upon the achievement of regulatory approval for DAXI or DaxibotulinumtoxinA Topical by the Company. In December 2012, Medicis was subsequently acquired by Valeant Pharmaceuticals International Inc., now known as Bausch Health Companies Inc. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that the settlement provisions related to the proceeds sharing arrangement payment in (ii) above and product approval payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the Company’s liability for the product approval payment was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured using a term of </span><span style="font-family:inherit;font-size:10pt;"><span>1.1 years</span></span><span style="font-family:inherit;font-size:10pt;">, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.7%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>7.5%</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the Company’s liability for the product approval payment was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured using a term of </span><span style="font-family:inherit;font-size:10pt;"><span>1.5 years</span></span><span style="font-family:inherit;font-size:10pt;">, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span>2.6%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>8.0%</span></span><span style="font-family:inherit;font-size:10pt;">. The term is based on an expected Biologics License Application (“BLA”) approval in 2020. For the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018, no payment was made for the product approval payment.</span></div>
CY2019Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	206720000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	42000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	206762000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	171784000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	171776000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	206762000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	171776000	USD
	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	0	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2019Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P14Y
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1425000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	4193000	USD
CY2019Q3	us-gaap	Variable Lease Cost VariableLeaseCost	298000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	886000	USD
CY2019Q3	us-gaap	Lease Cost LeaseCost	1723000	USD
	us-gaap	Lease Cost LeaseCost	5079000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1633000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6735000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6942000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5464000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5557000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	17959000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	44290000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	14195000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	30095000	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.120
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	5826000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	6011000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	6196000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4696000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	20173000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	42902000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	4704000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3890000	USD
	rvnc	Indemnification Liability Recordedduring Period IndemnificationLiabilityRecordedduringPeriod	0	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4303000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4092000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12882000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12422000	USD
	rvnc	Increase Decreasein Deferred Tax Assets IncreaseDecreaseinDeferredTaxAssets	15000000	USD

Files In Submission

Name	View Source	Status
0001479290-19-000109-index-headers.html	Edgar Link	pending
0001479290-19-000109-index.html	Edgar Link	pending
0001479290-19-000109.txt	Edgar Link	pending
0001479290-19-000109-xbrl.zip	Edgar Link	pending
ex101q31910qmylan.htm	Edgar Link	pending
ex102q31910qseparation.htm	Edgar Link	pending
ex103q31910qseverancep.htm	Edgar Link	pending
ex104q31910qmarkfoley.htm	Edgar Link	pending
ex105q319nonemployeedi.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20190930.xsd	Edgar Link	pending
rvnc-20190930_cal.xml	Edgar Link	unprocessable
rvnc-20190930_def.xml	Edgar Link	unprocessable
rvnc-20190930_lab.xml	Edgar Link	unprocessable
rvnc-20190930_pre.xml	Edgar Link	unprocessable
rvnc-q319exhibit311.htm	Edgar Link	pending
rvnc-q319exhibit312.htm	Edgar Link	pending
rvnc-q319exhibit321.htm	Edgar Link	pending
rvnc-q319exhibit322.htm	Edgar Link	pending
rvncq31910q.htm	Edgar Link	pending
rvncq31910q_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2019 Q4 Form 10-Q Financial Statement

#000147929019000109 Filed on November 04, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2019 Q4 Form 10-Q Financial Statement

#000147929019000109 Filed on November 04, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc